"*" indicates required fields
If you need a product to meet a specific quality requirement, bulk quantity or packaging formats, Please use this form to request price and lead time.
"*" indicates required fields
In this webinar, Scott Patterson, Vice President of Pharma and Biopharma Technical Support at ILC Dover, provides an in-depth exploration of the DoverPac® flexible containment system and its applications in pharmaceutical manufacturing. Scott highlights how the single-use DoverPac® enhances safety, reduces cross-contamination risks, and simplifies processes like chemical synthesis and oral solid dosage production. He […]
In this webinar, Scott Patterson, Vice President of Pharma and Biopharma Technical Support, and David Howes, Product and New Business Development Manager, highlight how flexible containment systems and the Atmospheric Control Module (ACM) address the challenges of milling and micronizing potent drug compounds. They explore how these innovations enhance safety, reduce complexity, and optimize processes […]
This webinar, presented by Scott Patterson, Vice President, Pharma/BioPharma, delves into advanced solutions for handling powders in upstream biopharmaceutical manufacturing. The discussion highlights common challenges such as minimizing operator exposure, improving powder transfer efficiency, and reducing operational waste in the pharmaceutical and biopharmaceutical sectors. With a focus on innovative ILC Dover technologies like the EZ […]
In this webinar, Martyn Ryder, Business and Product Development Manager at SOLO Containment, an ILC Dover Company, delves into the transformative impact of ILC Dover’s full life cycle safety innovation on high-containment pharmaceutical and biopharmaceutical manufacturing. He highlights how advanced flexible film isolator technology is redefining containment practices, ensuring unmatched safety for operators, and optimizing […]
In a recent webinar, DoverPac® for HPAPI Transfers, ILC Dover discussed the two key benefits of DoverPac® technology: superior powder flow properties and zero cleaning.DoverPac technology is purpose-built to handle highly potent active pharmaceutical ingredients (HPAPIs) with precision and safety, streamlining critical transfers in pharmaceutical processes. DoverPac offers high containment, exceptional powder flow, and single-use […]
In this webinar, Scott Patterson, Vice President of Technical Sales, PharmBio at ILC Dover, will introduce the DoverPac® FIBC, a high-containment system designed for safe, efficient powder transfer in pharmaceutical processes. DoverPac’s single-use design eliminates cleaning requirements, delivering significant cost savings and production efficiencies. Its flexible wall technology ensures superior mass flow and complete discharge, […]
In this webinar, Martyn Ryder, Business and Product Development Manager at SOLO Containment, an ILC Dover Company, explores the groundbreaking role of flexible film isolator technology in advancing pharmaceutical and biopharmaceutical manufacturing. Martyn shares expert insights into how these innovative systems are reshaping high-containment environments, elevating safety standards, and optimizing operational efficiency. Martyn provides an […]
In this webinar, Martyn Ryder, Business and Product Development Manager at SOLO Containment, an ILC Dover Company, delves into the revolutionary impact of flexible film isolator technology on pharmaceutical and biopharmaceutical manufacturing. Martyn shares insights into how these cutting-edge systems are transforming high-containment environments, enhancing safety, and streamlining operations. Martyn provides a detailed overview of […]
In this webinar, Scott Patterson, Vice President of Pharma and Biopharma Technical Support at ILC Dover, and David Howes, Product and New Business Development Manager, delve into the transformative impact of flexible isolator technology on the pharmaceutical industry. Together, they explore how these advanced systems enhance operational efficiency and regulatory compliance, particularly in high-containment environments. […]
Antibody-drug conjugates (ADCs) are an advanced cancer therapy designed to precisely target and deliver cytotoxic agents directly to cancer cells. However, this approach introduces significant challenges in manufacturing, particularly in safely handling highly potent cytotoxic payloads. As the number of ADC candidates rises and regulatory safety standards become more stringent, the complexities of ADC manufacturing […]